These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 14594454

  • 1. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.
    Gründker C, Emons G.
    Reprod Biol Endocrinol; 2003 Oct 07; 1():65. PubMed ID: 14594454
    [Abstract] [Full Text] [Related]

  • 2. Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor.
    Gründker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B, Emons G.
    Eur J Endocrinol; 2004 Jul 07; 151(1):141-9. PubMed ID: 15248835
    [Abstract] [Full Text] [Related]

  • 3. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
    Gründker C, Völker P, Schulz KD, Emons G.
    Gynecol Oncol; 2000 Aug 07; 78(2):194-202. PubMed ID: 10926802
    [Abstract] [Full Text] [Related]

  • 4. Biology of the gonadotropin-releasing hormone system in gynecological cancers.
    Gründker C, Günthert AR, Westphalen S, Emons G.
    Eur J Endocrinol; 2002 Jan 07; 146(1):1-14. PubMed ID: 11751060
    [Abstract] [Full Text] [Related]

  • 5. Protein kinase C-independent stimulation of activator protein-1 and c-Jun N-terminal kinase activity in human endometrial cancer cells by the LHRH agonist triptorelin.
    Gründker C, Schlotawa L, Viereck V, Emons G.
    Eur J Endocrinol; 2001 Nov 07; 145(5):651-8. PubMed ID: 11720885
    [Abstract] [Full Text] [Related]

  • 6. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
    Gründker C, Völker P, Emons G.
    Endocrinology; 2001 Jun 07; 142(6):2369-80. PubMed ID: 11356684
    [Abstract] [Full Text] [Related]

  • 7. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
    Fister S, Günthert AR, Aicher B, Paulini KW, Emons G, Gründker C.
    Cancer Res; 2009 Aug 15; 69(16):6473-81. PubMed ID: 19638591
    [Abstract] [Full Text] [Related]

  • 8. Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells.
    Günthert AR, Gründker C, Böttcher B, Emons G.
    Anticancer Res; 2004 Aug 15; 24(3a):1727-32. PubMed ID: 15274347
    [Abstract] [Full Text] [Related]

  • 9. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
    Fister S, Schlotawa L, Günthert AR, Emons G, Gründker C.
    Gynecol Endocrinol; 2008 Jan 15; 24(1):24-9. PubMed ID: 17943530
    [Abstract] [Full Text] [Related]

  • 10. GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells.
    Eicke N, Günthert AR, Emons G, Gründker C.
    Int J Oncol; 2006 Nov 15; 29(5):1223-9. PubMed ID: 17016655
    [Abstract] [Full Text] [Related]

  • 11. GnRH antagonists in the treatment of gynecological and breast cancers.
    Emons G, Gründker C, Günthert AR, Westphalen S, Kavanagh J, Verschraegen C.
    Endocr Relat Cancer; 2003 Jun 15; 10(2):291-9. PubMed ID: 12790790
    [Abstract] [Full Text] [Related]

  • 12. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation.
    Gründker C, Günthert AR, Millar RP, Emons G.
    J Clin Endocrinol Metab; 2002 Mar 15; 87(3):1427-30. PubMed ID: 11889221
    [Abstract] [Full Text] [Related]

  • 13. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells.
    Emons G, Müller V, Ortmann O, Schulz KD.
    J Steroid Biochem Mol Biol; 1998 Apr 15; 65(1-6):199-206. PubMed ID: 9699874
    [Abstract] [Full Text] [Related]

  • 14. Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway.
    Kim KY, Choi KC, Auersperg N, Leung PC.
    Endocr Relat Cancer; 2006 Mar 15; 13(1):211-20. PubMed ID: 16601289
    [Abstract] [Full Text] [Related]

  • 15. Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen.
    Günthert AR, Gründker C, Olota A, Läsche J, Eicke N, Emons G.
    Eur J Endocrinol; 2005 Oct 15; 153(4):613-25. PubMed ID: 16189183
    [Abstract] [Full Text] [Related]

  • 16. Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells.
    Günthert AR, Gründker C, Hollmann K, Emons G.
    Biochem Biophys Res Commun; 2002 May 31; 294(1):11-5. PubMed ID: 12054733
    [Abstract] [Full Text] [Related]

  • 17. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo.
    Fister S, Günthert AR, Emons G, Gründker C.
    Cancer Res; 2007 Feb 15; 67(4):1750-6. PubMed ID: 17308117
    [Abstract] [Full Text] [Related]

  • 18. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
    Halmos G, Schally AV, Kahan Z.
    Int J Oncol; 2000 Aug 15; 17(2):367-73. PubMed ID: 10891548
    [Abstract] [Full Text] [Related]

  • 19. Autoregulation of the gonadotropin-releasing hormone (GnRH) system during puberty: effects of antagonistic versus agonistic GnRH analogs in a female rat model.
    Roth C, Schricker M, Lakomek M, Strege A, Heiden I, Luft H, Munzel U, Wuttke W, Jarry H.
    J Endocrinol; 2001 May 15; 169(2):361-71. PubMed ID: 11312152
    [Abstract] [Full Text] [Related]

  • 20. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines.
    Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Hölzel F, Schulz KD, Schally AV.
    Cancer Res; 1993 Nov 15; 53(22):5439-46. PubMed ID: 8221683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.